153 related articles for article (PubMed ID: 12508476)
1. [Faropenem 300 mg 3 times daily versus levofloxacin 100 mg 3 times daily in the treatment of urinary tract infections in patients with neurogenic bladder and/or benign prostatic hypertrophy].
Muratani T; Iihara K; Nishimura T; Inatomi H; Fujimoto N; Kobayashi T; Yamada Y; Takahashi K; Matsumoto T
Kansenshogaku Zasshi; 2002 Nov; 76(11):928-38. PubMed ID: 12508476
[TBL] [Abstract][Full Text] [Related]
2. Clinical evaluation of oral levofloxacin 500 mg once-daily dosage for treatment of lower respiratory tract infections and urinary tract infections: a prospective multicenter study in China.
Zhang YY; Huang HH; Ren ZY; Zheng HG; Yu YS; Lü XJ; Xiao ZK; Yang HF; Xiu QY; Chen BY; Yue HM; Hao QL; Huang JA; Ma H; Xiao W; Guo DY; Si B; Sun SH; Zhang W; Li QH; Shen HH; Duan J; Li HY; Yao WZ; Gu JM; Xia QM; Ying KJ; Liu A; Yang HP; Shi MH; Sun TY; Ding GH; Wu GM
J Infect Chemother; 2009 Oct; 15(5):301-11. PubMed ID: 19856068
[TBL] [Abstract][Full Text] [Related]
3. [Efficacy and safety of faropenem in pediatric patients with bacterial infectious diseases].
Yokota T; Azagami S; Abe T; Ozaki A; Ojima T; Koizumi Y; Jozaki K; Cho H; Nakao A; Nonoyama M; Bamba M; Hojo H; Sunakawa K
Jpn J Antibiot; 2008 Dec; 61(6):366-78. PubMed ID: 19288854
[TBL] [Abstract][Full Text] [Related]
4. A double-blind, randomized comparison of levofloxacin 750 mg once-daily for five days with ciprofloxacin 400/500 mg twice-daily for 10 days for the treatment of complicated urinary tract infections and acute pyelonephritis.
Peterson J; Kaul S; Khashab M; Fisher AC; Kahn JB
Urology; 2008 Jan; 71(1):17-22. PubMed ID: 18242357
[TBL] [Abstract][Full Text] [Related]
5. Treatment of complicated urinary tract infection and acute pyelonephritis by short-course intravenous levofloxacin (750 mg/day) or conventional intravenous/oral levofloxacin (500 mg/day): prospective, open-label, randomized, controlled, multicenter, non-inferiority clinical trial.
Ren H; Li X; Ni ZH; Niu JY; Cao B; Xu J; Cheng H; Tu XW; Ren AM; Hu Y; Xing CY; Liu YH; Li YF; Cen J; Zhou R; Xu XD; Qiu XH; Chen N
Int Urol Nephrol; 2017 Mar; 49(3):499-507. PubMed ID: 28108978
[TBL] [Abstract][Full Text] [Related]
6. [Efficacy of a single-day administration of levofloxacin for the prevention of urinary tract infections after urogenital examinations and treatments for outpatients].
Hayashi T; Sakai Y; Saito K; Arai G; Hyochi N; Suzuki M; Masuda H; Kawakami S; Okuno T; Kobayashi T; Kageyama Y; Kihara K
Hinyokika Kiyo; 2001 Nov; 47(11):773-5. PubMed ID: 11771168
[TBL] [Abstract][Full Text] [Related]
7. Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI).
Wagenlehner FM; Umeh O; Steenbergen J; Yuan G; Darouiche RO
Lancet; 2015 May; 385(9981):1949-56. PubMed ID: 25931244
[TBL] [Abstract][Full Text] [Related]
8. Continuous versus intermittent levofloxacin treatment in complicated urinary tract infections caused by urinary obstruction temporarily relieved by foreign body insertion.
Tenke P; Kovacs B; Benkõ R; Ashaber D; Nagy E
Int J Antimicrob Agents; 2006 Aug; 28 Suppl 1():S82-5. PubMed ID: 16857348
[TBL] [Abstract][Full Text] [Related]
9. Early discharge of hospitalised patients with community-acquired urosepsis when treated with levofloxacin in sequential therapy.
Concia E; Marchetti F;
Arch Ital Urol Androl; 2006 Sep; 78(3):112-4. PubMed ID: 17137026
[TBL] [Abstract][Full Text] [Related]
10. Randomized, double-blind, comparative study of levofloxacin and ofloxacin in the treatment of complicated urinary tract infections.
Peng MY
J Microbiol Immunol Infect; 1999 Mar; 32(1):33-9. PubMed ID: 11561568
[TBL] [Abstract][Full Text] [Related]
11. Bactericidal effect of levofloxacin on strains with equal susceptibility in an in vitro urinary bladder model.
Takahashi S; Sano M; Nishimura M; Matsukawa M; Mikami M; Hirose T; Tsukamoto T
Chemotherapy; 1998; 44(5):337-42. PubMed ID: 9732150
[TBL] [Abstract][Full Text] [Related]
12. [Clinical evaluation of faropenem against infections in pediatric fields].
Sunakawa K; Satoh Y; Iwata S; Terashima I; Meguro H; Kusumoto Y; Kato T; Akita H; Goshima T; Yokota T; Toyonaga Y; Ishihara T; Kanemura H; Iwai N; Nakamura H; Nakashima M
Jpn J Antibiot; 1997 Sep; 50(9):739-55. PubMed ID: 9394235
[TBL] [Abstract][Full Text] [Related]
13. A pilot study on prevention of catheter-related urinary tract infections with fluoroquinolones.
Esposito S; Noviello S; Leone S; Marvaso A; Drago L; Marchetti F;
J Chemother; 2006 Oct; 18(5):494-501. PubMed ID: 17127226
[TBL] [Abstract][Full Text] [Related]
14. Evaluation by Monte Carlo simulation of levofloxacin dosing for complicated urinary tract infections caused by Escherichia coli or Pseudomonas aeruginosa.
Deguchi T; Seike K; Yasuda M; Matsumoto T
J Infect Chemother; 2011 Oct; 17(5):726-30. PubMed ID: 21409530
[TBL] [Abstract][Full Text] [Related]
15. [Multicentric study for evaluation of levofloxacin in the treatment of complicated urinary tract infections].
Trinchieri A; Marchetti F
Arch Ital Urol Androl; 2003 Mar; 75(1):49-52. PubMed ID: 12741347
[TBL] [Abstract][Full Text] [Related]
16. A controlled trial of levofloxacin and lomefloxacin in the treatment of complicated urinary tract infection.
Klimberg IW; Cox CE; Fowler CL; King W; Kim SS; Callery-D'Amico S
Urology; 1998 Apr; 51(4):610-5. PubMed ID: 9586615
[TBL] [Abstract][Full Text] [Related]
17. Population pharmacokinetics of oral levofloxacin 500 mg once-daily dosage in community-acquired lower respiratory tract infections: results of a prospective multicenter study in China.
Zhang J; Xu JF; Liu YB; Xiao ZK; Huang JA; Si B; Sun SH; Xia QM; Wu XJ; Cao GY; Shi YG; Zhang YY
J Infect Chemother; 2009 Oct; 15(5):293-300. PubMed ID: 19856067
[TBL] [Abstract][Full Text] [Related]
18. [In vitro antibacterial activity of faropenem, a novel oral penem antibiotic, against enterohemorrhagic Escherichia coli O157 strains].
Nasu T; Okamoto K; Nakanishi T; Nishino T
Jpn J Antibiot; 1999 Aug; 52(8):541-53. PubMed ID: 10587879
[TBL] [Abstract][Full Text] [Related]
19. Outcomes of high-dose levofloxacin therapy remain bound to the levofloxacin minimum inhibitory concentration in complicated urinary tract infections.
Armstrong ES; Mikulca JA; Cloutier DJ; Bliss CA; Steenbergen JN
BMC Infect Dis; 2016 Nov; 16(1):710. PubMed ID: 27887579
[TBL] [Abstract][Full Text] [Related]
20. [Role of levofloxacin in the treatment of urinary tract infections].
Trinchiere A
Arch Ital Urol Androl; 2001 Jun; 73(2):105-13. PubMed ID: 11758533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
